| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Michele Wilson, Benjamin Gutierrez, Steve J Offord, Christopher M Blanchette, Anna Eramo, Stephanie Earnshaw, Siddhesh A Kama. Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia. Drugs in context. vol 5. 2016-04-26. PMID:27114739. |
inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia. |
2016-04-26 |
2023-08-13 |
Not clear |
| Michele Wilson, Benjamin Gutierrez, Steve J Offord, Christopher M Blanchette, Anna Eramo, Stephanie Earnshaw, Siddhesh A Kama. Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia. Drugs in context. vol 5. 2016-04-26. PMID:27114739. |
aripiprazole once-monthly (aom) has been shown to reduce total psychiatric hospitalizations among patients who switched from oral standard of care (soc) therapy to aom in a multicenter, open-label, mirror-image study of patients with schizophrenia. |
2016-04-26 |
2023-08-13 |
Not clear |
| William H Carson, Hisashi Kitagaw. Drug development for anxiety disorders: new roles for atypical antipsychotics. Psychopharmacology bulletin. vol 38. issue 1. 2016-04-23. PMID:15278017. |
the next generation antipsychotic, aripiprazole, has a unique mechanism of action (ie, combined d2 and 5-ht1a partial agonist and 5-ht2a antagonist) and improves depressive and depressive/anxiety symptoms in patients with schizophrenia. |
2016-04-23 |
2023-08-12 |
Not clear |
| Yoshiteru Takekita, Chiara Fabbri, Masaki Kato, Shinpei Nonen, Shiho Sakai, Naotaka Sunada, Yosuke Koshikawa, Masataka Wakeno, Gaku Okugawa, Toshihiko Kinoshita, Alessandro Serrett. HTR1A Gene Polymorphisms and 5-HT1A Receptor Partial Agonist Antipsychotics Efficacy in Schizophrenia. Journal of clinical psychopharmacology. vol 35. issue 3. 2016-04-19. PMID:25822479. |
perospirone or aripiprazole was administered to 100 patients with schizophrenia in a randomized controlled study. |
2016-04-19 |
2023-08-13 |
Not clear |
| Itaru Miura, Keiko Kanno-Nozaki, Mizuki Hino, Sho Horikoshi, Takafumi Ota, Hirobumi Mashiko, Shin-Ichi Niwa, Hirooki Yab. Influence of -141C Ins/Del Polymorphism in DRD2 Gene on Clinical Symptoms and Plasma Homovanillic Acid Levels in the Treatment of Schizophrenia With Aripiprazole. Journal of clinical psychopharmacology. vol 35. issue 3. 2016-04-19. PMID:25871573. |
influence of -141c ins/del polymorphism in drd2 gene on clinical symptoms and plasma homovanillic acid levels in the treatment of schizophrenia with aripiprazole. |
2016-04-19 |
2023-08-13 |
Not clear |
| Suneeta James, Chaya Kapugama, Mohammed Al-Uzr. Use of Aripiprazole Long Acting Injection in Negative Symptoms of Schizophrenia. Case reports in psychiatry. vol 2016. 2016-03-16. PMID:26981301. |
use of aripiprazole long acting injection in negative symptoms of schizophrenia. |
2016-03-16 |
2023-08-13 |
Not clear |
| Suneeta James, Chaya Kapugama, Mohammed Al-Uzr. Use of Aripiprazole Long Acting Injection in Negative Symptoms of Schizophrenia. Case reports in psychiatry. vol 2016. 2016-03-16. PMID:26981301. |
we report the case of a 34-year-old female of afro-caribbean origin, who presented with prominent negative symptoms of schizophrenia and was successfully treated with aripiprazole long acting injection. |
2016-03-16 |
2023-08-13 |
Not clear |
| Suneeta James, Chaya Kapugama, Mohammed Al-Uzr. Use of Aripiprazole Long Acting Injection in Negative Symptoms of Schizophrenia. Case reports in psychiatry. vol 2016. 2016-03-16. PMID:26981301. |
aripiprazole long acting injection promises benefits in the treatment of negative symptoms of schizophrenia. |
2016-03-16 |
2023-08-13 |
Not clear |
| Masayuki Takase, Nobuhisa Kanahara, Yasunori Oda, Hiroshi Kimura, Hiroyuki Watanabe, Masaomi Iy. Dopamine supersensitivity psychosis and dopamine partial agonist: a retrospective survey of failure of switching to aripiprazole in schizophrenia. Journal of psychopharmacology (Oxford, England). vol 29. issue 4. 2016-03-11. PMID:25735995. |
dopamine supersensitivity psychosis and dopamine partial agonist: a retrospective survey of failure of switching to aripiprazole in schizophrenia. |
2016-03-11 |
2023-08-13 |
Not clear |
| Masayuki Takase, Nobuhisa Kanahara, Yasunori Oda, Hiroshi Kimura, Hiroyuki Watanabe, Masaomi Iy. Dopamine supersensitivity psychosis and dopamine partial agonist: a retrospective survey of failure of switching to aripiprazole in schizophrenia. Journal of psychopharmacology (Oxford, England). vol 29. issue 4. 2016-03-11. PMID:25735995. |
the administration of aripiprazole (ari), a dopamine partial agonist, could provoke abrupt psychotic worsening in patients with schizophrenia. |
2016-03-11 |
2023-08-13 |
Not clear |
| Jing-Xu Chen, Yun-Ai Su, Qing-Tao Bian, Li-He Wei, Rong-Zhen Zhang, Yan-Hong Liu, Christoph Correll, Jair C Soares, Fu-De Yang, Shao-Li Wang, Xiang-Yang Zhan. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study. Psychoneuroendocrinology. vol 58. 2016-03-04. PMID:25981348. |
we aimed to evaluate the dose effects of adjunctive treatment with aripiprazole on prolactin levels and hyperprolactinemia in schizophrenia patients. |
2016-03-04 |
2023-08-13 |
human |
| Jing-Xu Chen, Yun-Ai Su, Qing-Tao Bian, Li-He Wei, Rong-Zhen Zhang, Yan-Hong Liu, Christoph Correll, Jair C Soares, Fu-De Yang, Shao-Li Wang, Xiang-Yang Zhan. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study. Psychoneuroendocrinology. vol 58. 2016-03-04. PMID:25981348. |
stable subjects 18-45 years old with schizophrenia and hyperprolactinemia (i.e., >24 ng/ml for females and >20 ng/ml for males) were randomly assigned to receive 8 weeks of placebo (n=30) or oral aripiprazole 5mg/day (n=30), 10mg/day (n=29), or 20mg/day (n=30) added on to fixed dose risperidone treatment. |
2016-03-04 |
2023-08-13 |
human |
| Manit Srisurapanont, Sirijit Suttajit, Narong Maneeton, Benchalak Maneeto. Efficacy and safety of aripiprazole augmentation of clozapine in schizophrenia: a systematic review and meta-analysis of randomized-controlled trials. Journal of psychiatric research. vol 62. 2016-03-02. PMID:25619176. |
efficacy and safety of aripiprazole augmentation of clozapine in schizophrenia: a systematic review and meta-analysis of randomized-controlled trials. |
2016-03-02 |
2023-08-13 |
Not clear |
| Manit Srisurapanont, Sirijit Suttajit, Narong Maneeton, Benchalak Maneeto. Efficacy and safety of aripiprazole augmentation of clozapine in schizophrenia: a systematic review and meta-analysis of randomized-controlled trials. Journal of psychiatric research. vol 62. 2016-03-02. PMID:25619176. |
we conducted a systematic review of randomized-controlled trials (rcts) to determine the efficacy and safety of aripiprazole augmentation of clozapine for schizophrenia. |
2016-03-02 |
2023-08-13 |
Not clear |
| Michael Tempest, Christophe Sapin, Maud Beillat, Paul Robinson, Maarten Treu. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK. The journal of mental health policy and economics. vol 18. issue 4. 2016-02-23. PMID:26729007. |
cost-effectiveness analysis of aripiprazole once-monthly for the treatment of schizophrenia in the uk. |
2016-02-23 |
2023-08-13 |
Not clear |
| Jonathan Knights, Shashank Rohatag. Development and application of an aggregate adherence metric derived from population pharmacokinetics to inform clinical trial enrichment. Journal of pharmacokinetics and pharmacodynamics. vol 42. issue 3. 2016-02-12. PMID:25821065. |
there were no trends observed between results from calculated aggregate adherence metrics and total scores from mmas8 in a single-visit clinical trial of 47 patients with bipolar 1 disorder or schizophrenia who were on stable doses of aripiprazole, although a strong association was observed for one mmas8 question. |
2016-02-12 |
2023-08-13 |
Not clear |
| Shinya Uchida, Shogo Hiraoka, Noriyuki Namik. Development of gummi drugs of aripiprazole as hospital formulations. Chemical & pharmaceutical bulletin. vol 63. issue 5. 2016-02-08. PMID:25948328. |
we aimed to develop a gummi drug that contains aripiprazole (which can reduce schizophrenia and manic symptoms in bipolar disorder). |
2016-02-08 |
2023-08-13 |
Not clear |
| P Ratajczak, E Nowakowska, K Kus, R Danielewicz, S Herman, A Woźnia. Neuroleptics and enrichment environment treatment in memory disorders and other central nervous system function observed in prenatally stressed rats. Human & experimental toxicology. vol 34. issue 5. 2016-01-11. PMID:25062975. |
it is believed that the most effective method of treatment in schizophrenia is pharmacotherapy, in particular, the use of atypical neuroleptics like aripiprazole (ari) and olanzapine (ola). |
2016-01-11 |
2023-08-13 |
rat |
| Jun Ishigooka, Jun Nakamura, Yasuo Fujii, Nakao Iwata, Toshifumi Kishimoto, Masaomi Iyo, Naohisa Uchimura, Ryoji Nishimura, Naoaki Shimiz. Efficacy and safety of aripiprazole once-monthly in Asian patients with schizophrenia: a multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole. Schizophrenia research. vol 161. issue 2-3. 2015-12-31. PMID:25556976. |
efficacy and safety of aripiprazole once-monthly in asian patients with schizophrenia: a multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole. |
2015-12-31 |
2023-08-13 |
Not clear |
| Jun Ishigooka, Jun Nakamura, Yasuo Fujii, Nakao Iwata, Toshifumi Kishimoto, Masaomi Iyo, Naohisa Uchimura, Ryoji Nishimura, Naoaki Shimiz. Efficacy and safety of aripiprazole once-monthly in Asian patients with schizophrenia: a multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole. Schizophrenia research. vol 161. issue 2-3. 2015-12-31. PMID:25556976. |
this study was designed to evaluate efficacy and safety of aripiprazole once-monthly (aom) by verifying non-inferiority of aom to oral aripiprazole in asian patients with schizophrenia. |
2015-12-31 |
2023-08-13 |
Not clear |